Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Rating of “Buy” by Brokerages

Scholar Rock Holding Corporation (NASDAQ:SRRK) has earned an average recommendation of “Buy” from the seventeen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and four have given a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $51.1429.

SRRK has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Citigroup initiated coverage on shares of Scholar Rock in a research note on Friday, January 9th. They set a “buy” rating and a $55.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Finally, Barclays increased their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 136,462 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02. Following the sale, the insider directly owned 108,964 shares in the company, valued at approximately $4,926,262.44. The trade was a 55.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Vikas Sinha sold 16,755 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $715,438.50. Following the completion of the transaction, the chief financial officer owned 583,245 shares of the company’s stock, valued at approximately $24,904,561.50. This represents a 2.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 344,932 shares of company stock worth $15,371,225 over the last ninety days. 13.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Scholar Rock

Several large investors have recently modified their holdings of the business. IFP Advisors Inc raised its position in shares of Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after purchasing an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Scholar Rock in the fourth quarter valued at $30,000. Summit Securities Group LLC acquired a new stake in shares of Scholar Rock during the fourth quarter valued at $31,000. Ramirez Asset Management Inc. purchased a new stake in Scholar Rock during the 3rd quarter worth about $37,000. Finally, EverSource Wealth Advisors LLC increased its position in Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after purchasing an additional 525 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Scholar Rock Trading Down 0.1%

NASDAQ SRRK opened at $46.97 on Thursday. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $4.79 billion, a P/E ratio of -14.91 and a beta of 0.67. Scholar Rock has a 52-week low of $22.71 and a 52-week high of $49.82. The firm has a 50-day moving average price of $45.31 and a 200 day moving average price of $38.68.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).